Inside the American and European Peptide Supply Chain

Educational content only. Not medical advice. FeelGood does not claim that any peptide treats, cures, prevents, or mitigates any disease or condition. Consult a qualified healthcare provider before making any decisions about peptide therapy.

Roughly nine out of every ten peptide products on the US market are manufactured at a small number of facilities in China and the surrounding region. The remaining slice comes from a much smaller set of facilities in the United States and Europe. The label on the package almost never says which one. The buyer is left to triangulate from disclosures the seller chooses to publish, which in most of the market means triangulating from nothing.

This article is about that supply chain. Who actually makes peptides for the US market, how peptide quality is documented when it is documented at all, what an ISO 17025 accreditation proves, and where the line sits between a research-grade vial and a pharmaceutical-grade one. It is written for the reader who has noticed that the wellness market sells the same molecule at five different price points with five different claims and wants to know what, if anything, distinguishes them.

The structure of the global peptide supply

Peptide manufacturing is a chemistry problem before it is a wellness one. Synthesizing a peptide means assembling a chain of amino acids in a defined sequence, usually through solid-phase peptide synthesis, then purifying the product, characterizing it, and packaging it. The synthesis itself has been industrialized since the 1980s. The economic geography of who does that industrial work has consolidated in three places.

China is the largest manufacturer of active pharmaceutical ingredients for the global market by volume, including the peptide segment. The Chinese Pharmacopoeia and the export-oriented API facilities in Hangzhou, Hefei, Suzhou, and similar industrial hubs supply most of the peptide product that reaches the US through the research-chemical channel and a meaningful share of what reaches it through compounding pharmacies.1 The cost advantage is substantial. The quality variation, by the standards the FDA applies to drug ingredients, is also substantial.

Europe maintains a smaller but more tightly regulated peptide manufacturing base, with facilities concentrated in Switzerland, Germany, Italy, and Belgium. These are typically pharmaceutical-grade facilities operating under EU Good Manufacturing Practice and registered with the European Medicines Agency. They supply the prescription drug market first, the compounding market second, and the research market third when capacity allows.

The United States operates a smaller manufacturing base than Europe, though one that has grown since 2020. Bachem opened a US manufacturing facility in 2019. PolyPeptide Group operates from Torrance, California. Smaller specialty manufacturers have grown around the integrative medicine and 503A compounding channels. These facilities are FDA-registered and inspected. Their per-gram costs are among the highest in the global market and their documentation is among the most thorough.

The pricing gradient across these three regions is roughly five to one, with Chinese material at the low end and US pharmaceutical-grade at the top. The quality gradient is harder to summarize because quality in peptide manufacturing is not a single variable.

What "quality" means in peptide manufacturing

A peptide product can fail quality in at least five ways. Each requires a different analytical test to detect.

Identity. The molecule in the vial is the molecule on the label. Confirmed by mass spectrometry, which measures the exact mass of the synthesized peptide and compares it to the theoretical mass. A peptide with an incorrect sequence will show a different mass and fail this test.

Purity. The percentage of the contents that is the intended peptide rather than synthesis byproducts, truncated sequences, or impurities. Measured by high-performance liquid chromatography (HPLC) and reported as a percentage. Pharmaceutical-grade peptides typically test at 98 percent purity or higher. Research-chemical material varies widely and frequently sits below 95 percent.

Endotoxin content. Bacterial endotoxins are residues from microbial contamination during manufacturing. They can cause acute pyrogenic reactions if present in injectable product. Measured by the Limulus Amebocyte Lysate (LAL) assay. The US Pharmacopeia specifies endotoxin limits for parenteral preparations, and pharmaceutical-grade peptides are tested against those limits.2

Sterility. For lyophilized injectables, the absence of viable microorganisms in the finished product. Tested by microbial culture under USP standards.

Stability. The peptide remains intact, in the correct form, for the labeled shelf life under the labeled storage conditions. Tested through accelerated stability protocols and confirmed across the product's shelf life.

A peptide can pass identity and fail purity, pass purity and fail endotoxin, pass both and fail sterility. A certificate of analysis (COA) that reports only one of these tests is documenting one of these dimensions. A buyer who sees a COA showing 99 percent HPLC purity and concludes the product is pharmaceutical-grade has answered one question out of five.

ISO 17025 accreditation, briefly

ISO/IEC 17025 is the international standard for the competence of testing and calibration laboratories. A laboratory accredited under ISO 17025 has demonstrated to an accreditation body (in the US, typically A2LA or ANAB) that it operates a documented quality management system, that its personnel are competent, that its methods are validated, and that its results are traceable to recognized standards.3

An ISO 17025 accreditation does not certify the product. It certifies the laboratory that tested the product. A COA from an ISO 17025 accredited laboratory means that the test results on the COA were produced under a recognized quality system. It does not mean the manufacturer is regulated, that the production facility is FDA-registered, or that the peptide meets any particular specification. The accreditation reduces the probability that the COA's numbers are themselves wrong. It does not reduce the probability that the peptide on the COA is the same peptide in the vial the customer receives.

Linking COA to vial requires batch-specific testing and chain-of-custody documentation. A vendor that publishes a generic COA for a product, with no batch number that matches the batch shipped to the customer, has not actually documented the customer's product. The COA documents some prior batch, possibly a representative sample, possibly something else. Batch-specific COAs are the only documentation that connects test results to the material the customer receives.

FDA registration and inspection

FDA-registered drug establishments, both foreign and domestic, are listed in the agency's Drug Establishments Current Registration Site (DECRS) database. The database is public.4 A buyer who wants to know whether a manufacturing facility is registered with the FDA can search the database directly.

FDA registration is not equivalent to FDA approval. A registered facility is one that has notified the FDA of its existence and submitted to potential inspection. The facility's products may or may not be approved drugs. Registration is the minimum bar for any facility supplying material into the US prescription drug supply chain. It is not required for facilities supplying research chemicals, which is one of the reasons the research-chemical channel exists.

FDA inspection is a separate process. The agency conducts inspections of registered facilities on a risk-based schedule. The frequency depends on the facility's history, the products it manufactures, and resource availability. Inspection findings are published in the FDA's Form 483 database when violations are observed. A facility that has been inspected, has no recent 483 findings, and supplies into the US pharmaceutical chain operates under a different regime than a facility that is unregistered, uninspected, and supplies into the research channel.

The research-chemical channel and its supply gaps

Most peptides sold to US consumers under "research use only" labeling are sourced from facilities that operate outside FDA registration. The supply chain that supports this channel is usually two-step: a manufacturer in China or the surrounding region produces bulk peptide, a US-based distributor purchases it, sometimes adds limited testing, and sells it under a brand name to consumers and laboratories. The distributor's relationship to the manufacturer is contractual, not custodial. Chain-of-custody documentation between manufacturing batch and consumer vial typically does not exist at all.

This matters operationally because the things that can go wrong in peptide manufacturing do not become visible to the end user. A vial that is 92 percent pure rather than 98 percent looks the same as a vial that is 99 percent. A peptide with a single-amino-acid sequence error has the same physical appearance as the correctly synthesized product. A lyophilized powder contaminated with endotoxins is visually indistinguishable from a clean preparation. The buyer has no native way to evaluate quality. The documentation is the only signal, and in most of the research-chemical channel the documentation does not exist.

The FDA's enforcement record over the past 18 months has focused on this segment of the market. The agency's December 2024 warning letter to Summit Research Peptides cited the company's marketing practices, but it also flagged the broader supply chain problem: peptide products sold without verified sourcing, without batch-specific testing, and without compliance with the labeling and quality standards that apply to drug-intended products.5 The December 2025 warning letter to Pinnacle Professional Research raised similar issues.6 The pattern in both letters is consistent: the FDA reads the surrounding evidence to establish intended use, and the disclaimers do not function as legal shields when the underlying supply chain practices match the patterns the agency has flagged.

The pharmaceutical-grade alternative

Pharmaceutical-grade peptide supply, by contrast, operates inside a documented chain. The manufacturing facility is FDA-registered or operates under an equivalent foreign regulatory authority. The synthesis follows validated methods. Each batch is tested for identity, purity, endotoxin content, and any other specifications relevant to the intended use. A batch-specific COA documents the test results. The COA links to a lot number that appears on the customer's vial. The testing is conducted by an ISO 17025 accredited laboratory, either in-house or by a contract testing organization. The documentation persists for the product's shelf life and beyond.

This is the standard the prescription drug market operates under. It is also the standard a small number of premium peptide brands and 503A compounding pharmacies have voluntarily adopted for products that the FDA has not classified as approved drugs. The added cost reflects the documentation and testing burden. The result is a product that the buyer can verify, independently, against the published documentation.

What documentation actually demonstrates

A peptide product with full documentation can be verified across four questions:

Where was the API manufactured? Answered by the manufacturing facility name and address, which can be cross-referenced against FDA registration databases and EU GMP certifications.

What was the synthesis method, and was it validated? Answered by the technical data file maintained by the manufacturer, summarized in the COA.

What did this specific batch test for? Answered by the batch-specific COA, with results for identity (mass spec), purity (HPLC), endotoxin content (LAL), and any other relevant specifications.

Who performed the testing? Answered by the testing laboratory's name, address, and accreditation status, listed on the COA.

A vendor that publishes this documentation makes the supply chain auditable. A vendor that does not is asking the customer to trust an unverified claim. The wellness market generally operates on unverified claims. The pharmaceutical market does not.

The current state of the US peptide market

STAT News reported in February 2026 on the broader BPC-157 supply chain, noting the consistent finding that the peptide products sold under that name through US research-chemical channels showed wide variation in actual content, purity, and identity when independently tested.7 The reporting tracks with similar findings from the GLP-1 enforcement environment, where the FDA has issued more than 50 warning letters since September 2025 citing compounding pharmacies and research vendors for product quality and supply chain documentation failures.8

MIT Technology Review's February 2026 piece on the peptide market summarized the broader situation: the regulatory and supply chain gaps that allowed the research-chemical channel to operate at scale are closing, and the brands that survive the transition will be those that can produce verifiable supply chain documentation.9 BioPharma Dive's April 2026 reporting on the FDA's planned PCAC review of 12 peptides reinforced the same point from the regulator's side.10

What this means for the buyer who reads documentation

A buyer evaluating a peptide product has three substantive questions to ask the seller, in this order.

First, where is the active pharmaceutical ingredient manufactured, and is the facility FDA-registered or operating under an equivalent foreign regulatory authority? An answer that names a specific facility and provides a registration number is the answer that can be verified. An answer that says "premium quality sourcing" or "carefully selected partners" is not.

Second, is the COA for this specific batch, and does the batch number on the COA match the lot number on the vial? A generic COA is not the same document. A batch-specific COA establishes the chain between test result and product.

Third, was the testing performed by an ISO 17025 accredited laboratory, and is the laboratory's accreditation current and verifiable through the accreditation body's database? The accreditation bodies (A2LA, ANAB) maintain searchable public databases of accredited laboratories.11

A peptide product that answers all three questions affirmatively is a documented product. A product that cannot answer one of them is selling on trust, which the FDA's recent warning letters and the STAT and Endpoints reporting suggest is no longer a defensible position in this market.

A closing note on this article's framing

FeelGood operates under the supply chain practices described above. The brand sources from US and European manufacturing facilities, publishes batch-specific COAs from ISO 17025 accredited laboratories, and documents the chain of custody from API to finished product. The article is not a product page. It is the editorial context for a category that has, until recently, operated without the documentation standards the prescription drug market takes for granted. The standards are not exotic. They are the baseline that drug manufacturing has applied for decades. The question facing the peptide market over the next 24 months is whether the consumer-facing brands meet that baseline or whether the FDA closes the channel that lets them avoid it.

Footnotes

1. LegitScript, "Understanding Peptides: A Q&A Guide for Payment Processors," October 2025. https://www.legitscript.com/wp-content/uploads/2025/10/Peptides-for-Payment-Processors-Guide.pdf
   
2. United States Pharmacopeia, General Chapter <85> Bacterial Endotoxins Test, current edition. USP-NF. Standard reference for the LAL assay in parenteral preparations. [verify current chapter number with counsel]
3. International Organization for Standardization, ISO/IEC 17025:2017, "General requirements for the competence of testing and calibration laboratories." https://www.iso.org/standard/66912.html
   
4. FDA Drug Establishments Current Registration Site (DECRS). https://www.accessdata.fda.gov/scripts/cder/drls/default.cfm
   
5. FDA Warning Letter to Summit Research Peptides, MARCS-CMS 695607, December 10, 2024. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/summit-research-peptides-695607-12102024
   
6. FDA Warning Letter to Pinnacle Professional Research dba Pinnacle Peptides, MARCS-CMS 719337, December 12, 2025.
7. STAT News, "BPC-157: The peptide with big claims and scant evidence," February 2026. https://www.statnews.com/2026/02/03/bpc-157-peptide-science-safety-regulatory-questions/
   
8. Wilson Sonsini Goodrich & Rosati, "FDA Sends Warning Letters to More Than 50 GLP-1 Compounders and Manufacturers," October 2025. https://www.wsgr.com/en/insights/fda-sends-warning-letters-to-more-than-50-glp-1-compounders-and-manufacturers.html
   
9. MIT Technology Review, "Peptides are everywhere. Here is what you need to know," February 2026. https://www.technologyreview.com/2026/02/23/1133522/peptides-are-everywhere-heres-what-you-need-to-know/
   
10. BioPharma Dive, "FDA moves toward easing restrictions on certain peptides," April 2026. https://www.biopharmadive.com/news/fda-peptides-rfk-advisory-committee-restrictions/817685/
    
11. A2LA (American Association for Laboratory Accreditation), accredited laboratory directory. https://www.a2la.org/directory-search. ANAB (ANSI National Accreditation Board), accredited laboratory directory. https://search.anab.org/
    
12. Frier Levitt, "Regulatory Status of Peptide Compounding in 2025," January 2026. https://www.frierlevitt.com/articles/regulatory-status-of-peptide-compounding-in-2025/
    
13. RAPS, "FDA considers adding a dozen peptides to its bulk drug compounding list," April 2026. https://www.raps.org/resource/fda-considers-adding-a-dozen-peptides-to-its-bulk-drug-compounding-list.html
    
14. Federal Register Docket FDA-2025-N-6895, FDA Pharmacy Compounding Advisory Committee, public comment record. https://www.regulations.gov/docket/FDA-2025-N-6895